Deltec Asset Management LLC Has $22.62 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Deltec Asset Management LLC lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 0.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,600,073 shares of the biopharmaceutical company’s stock after purchasing an additional 9,808 shares during the period. Ocular Therapeutix accounts for about 4.5% of Deltec Asset Management LLC’s portfolio, making the stock its 5th largest position. Deltec Asset Management LLC’s holdings in Ocular Therapeutix were worth $22,621,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OCUL. Atlas Capital Advisors LLC acquired a new position in Ocular Therapeutix during the 2nd quarter worth $34,000. Amalgamated Bank raised its position in shares of Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 1,015 shares during the period. Algert Global LLC bought a new position in Ocular Therapeutix in the second quarter valued at about $69,000. Finally, Bayesian Capital Management LP acquired a new stake in Ocular Therapeutix in the first quarter worth about $94,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Trading Down 0.6 %

OCUL opened at $11.30 on Wednesday. The firm’s fifty day moving average is $9.37 and its two-hundred day moving average is $7.57. The firm has a market cap of $1.76 billion, a PE ratio of -8.37 and a beta of 1.29. Ocular Therapeutix, Inc. has a twelve month low of $2.00 and a twelve month high of $11.77. The company has a debt-to-equity ratio of 0.18, a quick ratio of 16.55 and a current ratio of 16.64.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The firm had revenue of $16.40 million during the quarter, compared to the consensus estimate of $15.85 million. During the same quarter in the prior year, the company earned ($0.27) EPS. Ocular Therapeutix’s quarterly revenue was up 7.9% on a year-over-year basis. Equities research analysts anticipate that Ocular Therapeutix, Inc. will post -1.02 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on OCUL. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. Robert W. Baird reduced their price objective on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Finally, Scotiabank assumed coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $16.57.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.